These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33614957)

  • 21. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin-releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy.
    Witchel SF; Baens-Bailon RG; Lee PA
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1353-6. PubMed ID: 8636332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Use of Morning Urinary Gonadotropins and Sex Hormones in the Management of Early Puberty in Chinese Girls.
    Zhan S; Huang K; Wu W; Zhang D; Liu A; Dorazio RM; Shi J; Ullah R; Zhang L; Wang J; Dong G; Ni Y; Fu J
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4520-e4530. PubMed ID: 34160619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of HPGA suppression on predicted adult height in girls with central precocious puberty].
    Tao YH; Zeng BH; Sharif N
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Oct; 17(10):1093-7. PubMed ID: 26483231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy.
    Neely EK; Silverman LA; Geffner ME; Danoff TM; Gould E; Thornton PS
    Int J Pediatr Endocrinol; 2013 Dec; 2013(1):20. PubMed ID: 24295437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine.
    Roth CL; Brendel L; Rückert C; Hartmann K
    Horm Res; 2005; 63(5):257-62. PubMed ID: 15995342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test.
    Ibáñez L; Potau N; Zampolli M; Virdis R; Gussinyé M; Carrascosa A; Saenger P; Vicens-Calvet E
    J Clin Endocrinol Metab; 1994 Jan; 78(1):30-5. PubMed ID: 7507123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle.
    Trueman JA; Tillmann V; Cusick CF; Foster P; Patel L; Hall CM; Price DA; Clayton PE
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):223-30. PubMed ID: 12153601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trial.
    Li WJ; Gong CX; Guo MJ; Xing J; Li T; Song WH; Luo XP; Wu D; Liang JP; Cao BY; Gu Y; Su C; Liang XJ; Liu M; Wang R; Li FT
    Chin Med J (Engl); 2015 May; 128(10):1314-20. PubMed ID: 25963350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone.
    Vottero A; Pedori S; Verna M; Pagano B; Cappa M; Loche S; Bernasconi S; Ghizzoni L
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1284-7. PubMed ID: 16449342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic evaluation of central precocious puberty in girls.
    Yeh SN; Ting WH; Huang CY; Huang SK; Lee YC; Chua WK; Lin CH; Cheng BW; Lee YJ
    Pediatr Neonatol; 2021 Mar; 62(2):187-194. PubMed ID: 33388255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overnight luteinizing and follicle stimulating hormone profiles during GnRHa treatment in short girls born small for gestational age.
    van der Kaay DC; de Jong FH; Laven JS; Hokken-Koelega AC
    J Pediatr Endocrinol Metab; 2009 Feb; 22(2):161-9. PubMed ID: 19449673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pattern of gonadotropin and estradiol secretion in exaggerated thelarche.
    Garibaldi LR; Aceto T; Weber C
    Acta Endocrinol (Copenh); 1993 Apr; 128(4):345-50. PubMed ID: 8498153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
    Lewis KA; Goldyn AK; West KW; Eugster EA
    J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.
    Lewis KA; Eugster EA
    J Pediatr; 2013 Mar; 162(3):562-5. PubMed ID: 23040793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal serum luteinising hormone cut-off, and its utility and cost-effectiveness for aiding the diagnosis of the onset of puberty in girls with early stages of breast development.
    Wankanit S; Mahachoklertwattana P; Pattanaprateep O; Poomthavorn P
    Clin Endocrinol (Oxf); 2020 Jan; 92(1):46-54. PubMed ID: 31705682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
    Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors that predict a positive response on gonadotropin-releasing hormone stimulation test for diagnosing central precocious puberty in girls.
    Suh J; Choi MH; Kwon AR; Kim YJ; Jeong JW; Ahn JM; Chae HW; Kim DH; Kim HS
    Ann Pediatr Endocrinol Metab; 2013 Dec; 18(4):202-7. PubMed ID: 24904878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.